StockWatch
·

BOSTON SCIENTIFIC CORP Q3 FY26 Results

BSXQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue5.1K5.6%1.4%
Total Income5.1K5.6%1.4%
Expenditure4.3K1.1%7.3%
PBT733.0030.9%21.9%
Net Profit582.0035.8%22.9%
OPM16.11%5.53pp4.58pp
NPM11.33%5.34pp3.58pp
EPS0.4035.5%21.6%
View full financials

Boston Scientific Reports Q3 2026 Results with $5.138 Billion in Net Sales

28 Oct 2026 · 28 Oct, 4:06 pm

Summary

Boston Scientific announced third quarter 2026 net sales of $5.138 billion, a 1.5 percent increase year-over-year on reported, operational, and organic bases. The company reported GAAP net income of $582 million, or $0.40 per share, with adjusted EPS at $0.73 per share. Management expressed confidence in the long-term strategy despite a challenging year, highlighting the global teams' response to a cybersecurity incident and a strong pipeline of innovation.

Key Highlights

  1. 1

    Boston Scientific generated net sales of $5.138 billion during the third quarter of 2026, representing a 1.5 percent increase on a reported, operational, and organic basis compared to the prior year period.

  2. 2

    The company reported GAAP net income attributable to Boston Scientific common stockholders of $582 million or $0.40 per share for the third quarter of 2026.

  3. 3

    Adjusted EPS for the third quarter of 2026 was $0.73 per share, compared to $0.75 per share in the prior year period.

  4. 4

    MedSurg segment net sales increased by 0.6 percent on a reported basis to $1.733 billion, while Cardiovascular segment net sales grew by 1.9 percent to $3.406 billion in Q3 2026.

  5. 5

    Latin America and Canada (LACA) region demonstrated strong performance with net sales growth of 16.0 percent on a reported basis in Q3 2026.

  6. 6

    The company commenced enrollment in the Elite AF clinical trial for the WATCHMAN Elite™ Left Atrial Appendage Closure Device.

  7. 7

    Boston Scientific received U.S. FDA 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem and an expanded size offering for the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter.

Management Comments

M

Mike Mahoney

This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients. As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation.

Informational and educational content only. Not investment advice.